Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS1-1-01 tablets for moderate to severe major depressive disorder
CTR20260510Phase 2Active
- Sponsor
- Tasly Diyi Pharmaceutical
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JS1-1 in major depressive disorder (MDD), sponsored by Tasly Diyi Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
JS1-1
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20260510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260510.